Business Summary
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 21-01-12 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
Michael Breen
CEO | Chief Executive Officer | 61 | 21-01-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 96,230 | 0 | 0 | 89.34 % |
Stock B | 1 | 2,156,651 | 2,012,830 ( 93.33 %) | 0 |
Company contact information
GT Biopharma, Inc.
8000 Marina Boulevard Suite 100
94005, Brisbane
+415 919 4040
http://www.gtbiopharma.com![address Oxis International](https://cdn.zonebourse.com/static/address/25531677.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+57.14% | 848B | |
+31.64% | 627B | |
-0.67% | 363B | |
+15.40% | 318B | |
+12.29% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.02% | 179B | |
+3.16% | 167B |